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Background. Because of the increased risk of surgery, thyroid nodules causing compression signs and/or hyperthyroidism are
concerning during pregnancy. Patients andMethods. Six patients with nontoxic cystic, four with nontoxic solid, and three with overt
hyperthyroidism caused by toxic nodules were treated with percutaneous ethanol injection therapy (PEI). An average of 0.68mL
ethanol per 1mL nodule volume was administered. Mean number of PEI treatments for patients was 2.9. Success was defined as
the shrinkage of the nodule by more than 50% of the pretreatment volume (V0) and the normalization of TSH and FT4 levels.
The average V0 was 15.3mL. Short-term success was measured prior to labor, whereas long-term success was determined during
the final follow-up (an average of 6.8 years). Results.The pressure symptoms decreased in all but one patient after PEI and did not
worsen until delivery. The PEI was successful in 11 (85%) and 7 (54%) patients at short-term and long-term follow-up, respectively.
Three patients underwent repeat PEI which was successful in 2 patients. Conclusions. PEI is a safe tool and seems to have good
short-term results in treating selected symptomatic pregnant patients. Long-term success may require repeat PEI.
1. Introduction
Although the evaluation of a pregnant patient with a thyroid
nodule does not differ from other patients except in the use of
scintigraphy [1–3], the management of TN during pregnancy
is discussed only in the context of malignancy. The only
suggestion in the context of the management and therapy
of TN during pregnancy is the statement that levothyroxine
is not recommended during pregnancy [2]. The ATA guide-
lines published in 2011 recommend surgery in the case of
rapid nodule growth and/or if severe compressive symptoms
develop [4].
Data indicate that pregnancy is associated with an
increase in the size of preexisting nodules and with the
appearance of newly developed thyroid nodules, possibly
because of the negative iodine balance that frequently occurs
during pregnancy [5]. Depending on iodine intake, thyroid
nodules are present in 15.4 to 30.1% of pregnant women [6, 7].
Therapy (i.e., surgery of benign nodules) in such women
must be postponed after delivery if possible.Nevertheless, TN
causing pressure symptoms and/or hyperthyroidism raises
concern about appropriate therapy because surgery and gen-
eral anesthesia pose risks in pregnant women [8], and the use
of thyrostatic agents is not without risk. Although percuta-
neous ethanol injection therapy (PEI) is a useful alternative
to surgery in recurrent thyroid cysts and may have a limited
role in the case of solid TN, to the best of our knowledge, there
are only two publications focusing on [9] or mentioning [10]
PEI in the event of pregnancy. Based on this information, we
decided to analyze our experiences in this field.
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Table 1: Pretreatment clinical data on patients.
Age
(ys)
Gestational week
at 1st session
Degree of
compression1
Size of
nodule (mL)
Aspirated cystic
fluid (mL)
Number of
sessions
TSH
(mIU/L)
FT4
(pM/L)
Type of nodule
Nontoxic, cystic 22 16 2 17.9 9 3 1.01 13.9
Nontoxic, cystic 25 19 3 24.9 14 3 0.87 14.6
Nontoxic, cystic 29 16 3 30.6 24 3 3.01 12.7
Nontoxic, cystic 34 17 2 8.6 6.5 2 0.33 15.1
Nontoxic, cystic 39 18 3 11.9 5.7 3 2.39 18.4
Nontoxic, cystic 43 19 3 24.7 0.5 4 1.52 11.3
Nontoxic, solid 30 20 2 10.1 0 3 2.76 15.4
Nontoxic, solid 32 16 1 8.9 0 2 0.97 13.7
Nontoxic, solid 35 17 3 13.5 2.1 3 1.62 17.0
Nontoxic, solid 37 17 1 21.9 0 4 2.11 20.2
Toxic 20 16 1 13.8 2.9 3 0 43.9
Toxic 31 15 0 8.04 2.8 3 02 29.8
Toxic 39 13 0 4.32 0.7 2 2.912 8.05
Mean ± SD 326,86
1.84
1.14
15.3
8.0
2.92
0.64
1.663
0.89
15.23
2.67
1Degree of compression: 0: none; 1: occasionally in supine position; 2: continuous in supine position; 3: even in upstanding position.
2On propylthiouracil therapy.
3Themean TSH and FT4 values were calculated only in nontoxic nodules.
2. Patients and Methods
Between June 1996 andDecember 2013, 267 pregnant patients
with thyroid noduleswere evaluated in our thyroid outpatient
clinic. We offered PEI therapy to 10 patients with significant
pressure symptoms and to 3 patients with toxic nodules
with an FT4 level exceeding the upper normal value by
at least 30%. Eight women accepted our invitation. Five
other patients were evaluated in other thyroid departments
and were referred to us for PEI therapy. Thirteen pregnant
patients with thyroid nodules were treated with PEI. TSH,
FT4, anti-thyroid peroxidase antibody (aTPO), anti-human
thyroglobulin antibody (ahTG), and ultrasonography were
performed in all patients prior to PEI. Scintigraphy was
performed in 3 patients prior to their pregnancies. The
volume of the nodules was calculated as described by Brunn
et al. [11]. The clinical data are presented in Table 1.
The indications for PEI were the following: recurrent cyst
causing pressure symptoms in 6 patients and large nontoxic
solid nodule causing symptoms in 4 patients. Three patients
had toxic nodules, one of which caused symptoms, a second
of which increased by more than 100% in volume from the
5th to the 15th gestational week, and the third occurring in a
woman who was treated with propylthiouracil and exhibited
a neutrophil count of 1,300 (normal value 4,000–10,000) 2
weeks after initiating the thyrostatic drug. Prior to the PEI
treatment, malignancy was ruled out in all patients by fine
needle aspiration cytology. The aTPO and ahTG (Brahms,
Berlin, normal value <100U/mL) levels were normal in all
patients, as were the TSAb levels in the 3 patients exhibiting
hyperthyroidism. We asked the patients about the presence
of their compression signs. The degree of pressure symptoms
was defined as described in Tables 1 and 2.
In the case of nontoxic nodules, PEI was performed
between the 16th and the 22nd gestational week of pregnancy.
Patients with toxic nodules were treated as soon as possible
after the 13th gestational week of pregnancy.
Sterile 95% ethanol was injected under US control via a
23-G needle without anesthesia or pharmacological sedation.
Depending on the nodule size, the ethanol dose injected in
each session, which was administered slowly over 2 minutes,
varied from 1 to 6mL. In the case of cystic nodules, 90%
of the cystic volume was aspirated prior to PEI, and an
ethanol volume equivalent to 20% to 33% of the volume of the
aspirated fluid was injected. In the case of toxic and nontoxic
solid nodules, an ethanol volume representing between 20
and 30%of the initial volume of the nodule was administered.
PEI sessions were performed every 7 days except in the case
of toxic nodules, whichwere treated every 3 days (see Table 1).
Each patient received an average total dose of 0.68mL
ethanol (range 0.43–0.91mL) per milliliter nodular volume.
The ethanol was injected in an average of 2.92 (range 2–4)
outpatient sessions.
During PEI treatment, 2 patients were treated with
propylthiouracil, whichwas stopped on the day of the last PEI
session. Thyrostatic therapy was stopped in the 3rd patient
with a low neutrophil count before PEI therapy.
The follow-up protocol included physical examination;
US; TSH, FT4, aTPO, and ahTG measurements; and the
determination of degree of compression signs. The follow-up
was performed every 4 weeks during pregnancy and annually
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thereafter. In the case of toxic nodules, the first TSH and FT4
measurement was performed 2 weeks after the last PEI.
For nontoxic nodules, the outcome of the PEI treatment
was determined by US examination. Success was defined as
the≥50% shrinkage of the nodule relative to the pretreatment
volume every 8 weeks and during every follow-up occasion.
For toxic nodules, complete success required the fulfillment
of one additional condition: normal TSH and FT4 levels 4
weeks after PEI and later in the course without thyrostatic
therapy. We determined the short-term (until delivery) and
long-term (until the final follow-up examination) success of
PEI.
For statistical analysis, a repeated measures ANOVA test
was used to compare changes in the volume of the nodules
and inTSH levels, and the FriedmanANOVA test was applied
to compare changes in the degree of compression signs.
3. Results
3.1. Side Effects. In 7 of 18 sessions and in 17 of 20 sessions,
patients reported pain during the ethanol injection in the
cystic and noncystic nodule groups, respectively. The pain
radiated to the jaw and the teeth. With the exception of two
sessions, the pain decreased significantly over 2 to 3 minutes.
Pain stopped between 1 and 24 hours after injection in 2
patients.
Mild neck discomfort was reported in 28 of 38 sessions
and resolved within 24, 48, 96, and 124 hours after 11, 10, 6,
and 1 PEI session(s), respectively.
The voice of Patient 6 weakened after the last PEI. This
effect lasted for 36 hours, and her voice returned sponta-
neously without any treatment.
3.2. Change in the Degree of Pressure Symptoms. Eleven
patients suffered from various degrees of pressure symptoms
before PEI (see Table 2). In all but one patient, the degree
of compression decreased 4 weeks after the last PEI and
remained stable until delivery.The degrees of pressure symp-
toms were 1.84 ± 1.11, 0.31 ± 0.48, and 0.62 ± 0.968 (mean ±
SD) before the first PEI, at the last visit before delivery, and at
the final visit, respectively. The differences between the first
and second visit and between the first and final visit were
significant (𝑝 < 0.005 and 𝑝 < 0.011, resp.).
3.3. Short-Term Results (prior to Delivery). All but two
women delivered a healthy child between the 38th and 41st
gestational week. One woman (Patient 5) developed late-
onset preeclampsia (with hypertension and proteinuria) at
the 35th gestational week and delivered a healthy girl weigh-
ing 2730 g at the 36th gestational week. This patient was
treated for a recurrent cystic nodule between the 18th and
21st gestational week and was euthyroid at the onset of pre-
eclampsia. Patient 13 experienced a premature delivery at 33
weeks. She was treated for a toxic nodule between the 13th
and 14th gestationalweek and became euthyroid 2weeks later,
remaining euthyroid until the final visit 5 years later. She
delivered a baby weighing 2250 g at birth who was discharged
in a healthy condition 10 days after delivery. Ten women
experienced vaginal deliveries, and 3 underwent caesarean
deliveries. The reasons for caesarean were unrelated to thy-
roid disease.
For details of volume and biochemical data, see Table 2.
In all but one patient, the volume of the nodule at the last
predelivery visit was less than 50% of V0. In Patient 2, who
had a cystic nodule, the predelivery volume was 61.4% of V0.
The mean V0 was 15.3 ± 8.0mL, whereas the mean volume
at the last predelivery visit was 5.68 ± 4.01mL.The difference
was statistically significant (𝑝 < 0.0001).
Thyrostatic drugs were stopped on the day of the last PEI
in two patients and before the first PEI in the case of a third
patientwith a lowneutrophil count.TheFT4 level normalized
and remained stable in all patients after the first follow-
up visit and during the pregnancy. Two of the 3 patients
with toxic nodules remained euthyroid (i.e., the TSH became
and remained normal during their pregnancy), whereas the
3rd patient (Patient 11) with the largest nodule exhibited
subclinical hyperthyroidism later in the course of pregnancy
with a TSH in the range of 0.01–0.07mIU/L and with an
FT4 in the range of 12.1–15.0 pM/L. None of the patients was
treated with thyrostatic drug after the last PEI session.
ATPO and ahTG remained normal during pregnancy in
all patients.
Short-term success was reached in 11 of 13 patients; in
the remaining 2 women, compression signs ceased, and the
patients required neither thyrostatic therapy nor surgery until
labor.
3.4. Long-Term Results. Thyroid status gradually worsened in
Patient 11, who exhibited subclinical hyperthyroidism at the
last predelivery visit. Two years later, Patient 11 underwent
radioiodine therapy. The other 2 patients with toxic nodules
remained euthyroid, and the volume of their nodules did not
exceed 50% of V0 5 and 11 years after PEI, respectively.
In 3 of the 4 patients with nontoxic solid nodules, the
volume of the nodules exceeded 50% of V0, 7, 8, and 10 years
after PEI, respectively. It is worth noting that, one year earlier,
the volume of these nodules was less than 50% of V0. The
volume of the nodule of the fourth patient remained less than
50% of V0 3 years after her delivery.
PEI was unsuccessful during the short-term in Patient
2. Four of the remaining five patients with cystic nodules
exhibited a nodule volume less than 50%ofV0 at the last visit,
2, 6, 9, and 11 years after PEI, respectively.
The volume of the cystic nodule in Patient 5 was 25.0%
of V0 2 years after PEI, but, thereafter, she noticed a sudden
increase in size with a 98.3% volume of V0 29 months after
PEI.
The mean volume at the final visit was significantly lower
compared with V0 (7.0 ± 5.1mL and 15.3 ± 8.0mL, resp.,
𝑝 < 0.0001).The volume at the final visit was not significantly
greater than that at the last predelivery visit (𝑝 = 0.89).
ATPO and ahTG were normal in all patients at each
follow-up examination except for Patient 3, who was treated
for a cystic nodule. aTPO became elevated one year after
delivery (128U/mL) and fluctuated in the range of 61 and
143U/mL during the following 8 years.
Long-term success was reached in 7 of 13 patients with
one series of PEI.
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Table 3: The fate of patients with unsuccessful PEI therapy.
Number Type of nodule Age(ys)
Size of the
nodule before
first PEI
(V0), mL
Time
elapsed
until 2nd
therapy (ys)
Size of
nodule before
2nd therapy,
mL (% of V0)
Type of 2nd
therapy
Last visit
after the
2nd therapy
(ys)
Size of
nodule on
the last visit
(% of V0)
Final
result
2. Nontoxic, cystic 25 24.9 2 69.1 Repeated PEI 6 12.0 Success
5. Nontoxic, cystic 39 11.9 2 98.3 Repeated PEI 2 81.6 Surgery
7. Nontoxic, solid 30 10.1 7 78.2 Repeated PEI 2 37.8 Success
8. Nontoxic, solid1 32 8.9 10 68.5 No therapy —
10. Nontoxic, solid 37 21.9 8 70.8 Surgery —
11. Toxic 20 13.8 2 46.4 I-131 therapy —
1Although one PEI-series was unsuccessful in Patient 8, she requires no second therapy because her nodule causes no problem.
3.5. The Fate of Patients Whose PEI Was Unsuccessful. For
details, see Table 3. As mentioned earlier, Patient 11, who had
a toxic nodule, underwent radioiodine therapy 2 years after
PEI.
One series of PEI was unsuccessful in 3 of 4 patients with
nontoxic solid nodules. Patient 10 underwent surgery. Patient
7 repeated PEI therapy 7 years after the first PEI. Her nodule
was less than 37.8% of V0 2 years after the second PEI. The
nodule in Patient 8 was 68.5% of V0 10 years after PEI but did
not require surgery until recently.
PEI was unsuccessful in 2 of 6 patients with cystic
nodules. The volume of the nodule of Patient 2 was 69.1% of
V0 18 months after the first PEI, when she received 3 more
PEI sessions. Her nodule was 12.0% of V0 6 years after the
second session of PEI. We administered 3 more PEI sessions
29 months after the first PEI in Patient 5 with only transitory
success for another 2 years. Patient 5 subsequently underwent
lobectomy.
One series of PEI was unsuccessful in 6 patients. Three of
these patients underwent a repeat PEI, which was successful
in 2 but was unsuccessful in 1 patient.
4. Discussion
PEI therapy is an acceptedmethod for the treatment of recur-
rent thyroid cysts; however, it is not currently recommended
for solid nodules because of weak long-term results [1, 12].
Nevertheless, PEI may be a useful alternative to surgery in
the case of solid nodules under special circumstances, such
as recurrent nodules [13], iodine-induced hyperthyroidism
[14], particular cases of lymph node metastasis of papillary
carcinoma [15], large nodules inwhich themain goal is to gain
time (i.e., patients with poor life expectancy) [16], patients
with special professions, and pregnant patients [9, 14].
Thyrostatic therapy is relatively safe during pregnancy
and the surgical therapy of most pregnant patients can be
postponed after delivery. Nevertheless, in a small proportion
of pregnant patients with nodular goiter, mainly in those
presenting with significant compression or having significant
side effects of medical therapy, there is a need for alternative
therapy during pregnancy.
There are few publications in the field of PEI therapy
concerning pregnant women. Cortelazzi et al. published
a case report of a patient with a toxic nodule and stated that
PEImay be a safe therapy during pregnancy [9].Wepublished
our experience in 1999 with 2 pregnant patients with cystic
nodules and found that PEI therapywas safe and efficient [10].
With respect to the short-term goals, the pressure symp-
toms stopped or decreased in all but 1 of the 11 patients
presenting with the complaint before PEI, whereas FT4
became and remained normal without thyrostatic therapy
until delivery in all toxic patients. Statistically, PEI was not
fully successful in 2 patients. The volume of the nodule
remained greater than 50% of V0 at the last predelivery visit
(61.4%) in one woman. Nevertheless, her serious pretherapy
compression sign completely ceased after PEI and did not
recur later in the course. In one of the 3 toxic patients, theTSH
remained suppressed at the time of delivery, but the FT4 level
normalized and stabilized after PEI and until deliverywithout
thyrostatic therapy.
With respect to the long-term results (with an average
follow-up of 6.8 years), PEI was successful in 7 of 13 patients.
Compared with PEI in nonpregnant patients, this result
represents a lower response rate. Our most important goal
was to ensure optimal thyroid conditions until delivery with
minimal risk of any deleterious effects of PEI; therefore, we
administered only an average of 2/3 of the recommended
1mL ethanol per milliliter nodular volume. We think that
this amount explains the poor long-term results. Three
of 6 patients with unsuccessful PEI required surgery or
radioiodine therapy, and, in two patients, a repeated PEI was
successful 7 and 2 years after the second therapy, respectively.
The volume of the nodule in the sixth patient was 68.5% of V0
10 years after PEI but did not require surgery until recently.
An aTPO positivity may develop after PEI [17, 18]. This
effect would have been a potential drawback during preg-
nancy. No aTPO or ahTG positivity developed during preg-
nancy in our patients, and, later in the course, we observed
aTPO elevation in one patient one year after delivery.
The success of PEI decreased significantly with the length
of follow-up time. We determined PEI to be unsuccessful in
3 of 6 patients after more than 7 years of follow-up.
The present study demonstrates that PEI therapy may be
a useful alternative in pregnant patients with nodules causing
compression signs. No serious side effects occurred. All but 2
women delivered on time and had no complications during
6 International Journal of Endocrinology
their pregnancy and labor. Neither the premature delivery
of one woman at 33 weeks nor the late-onset preeclampsia
in another woman was related to thyroid disease or to PEI
therapy. While PEI may have a role in the therapy of large
cystic nodules causing compression signs, in solid nodules
laser or radiofrequency percutaneous thermoablation seems
to be more efficacious and less painful than PEI.
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